Sort
10,766 grants matching “checkpoint inhibitor”
Targeting Gq pathway in uveal melanoma
$445,160Xu Chen · University Of California, San Francisco · R01 · FY2023 · CA
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans
$445,000Stephanie Dougan · Dana-Farber Cancer Inst · R01 · FY2022 · AI
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans
$445,000Stephanie Dougan · Dana-Farber Cancer Inst · R01 · FY2024 · AI
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans
$445,000Stephanie Dougan · Dana-Farber Cancer Inst · R01 · FY2025 · AI
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans
$445,000Stephanie Dougan · Dana-Farber Cancer Inst · R01 · FY2023 · AI
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humans
$445,000Stephanie Dougan · Dana-Farber Cancer Inst · R01 · FY2021 · AI
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
$444,968Wei Gu · Columbia University Health Sciences · R01 · FY2024 · CA
Targeting exosomal PDL1 to improve immunotherapy
$444,750Wei Guo · Wistar Institute · P50 · FY2025 · CA
The Role of Epithelial-Mesenchymal Transition in Re-Wiring KRAS Mutant Lung Cancer
$444,653Don Lynn Gibbons · University Of Tx Md Anderson Can Ctr · R37 · FY2021 · CA
Targeting Epigenomic Regulators at the Replication Fork in PDAC
$444,584Gwen Lomberk · Medical College Of Wisconsin · R01 · FY2023 · CA
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.
$444,533Alexander H. Stegh · Washington University · R01 · FY2024 · CA
An innate immune checkpoint in cancer immunotherapy
$444,441Carla Rothlin · Yale University · R01 · FY2019 · CA
Epigenetic Regulation of Head and Neck Cancer Immune Evasion
$444,406Chao Lu · Columbia University Health Sciences · R01 · FY2024 · DE
Photodynamic therapy with prior inhibition of epidermal growth factor receptor to stimulate antitumor innate immune response
$444,397Theresa M Busch · University Of Pennsylvania · R01 · FY2019 · CA
Photodynamic therapy with prior inhibition of epidermal growth factor receptor to stimulate antitumor innate immune response
$444,397Theresa M Busch · University Of Pennsylvania · R01 · FY2020 · CA
Mutational signature analysis: methods and applications to the clinic
$444,343Peter Park · Harvard Medical School · R01 · FY2023 · CA
PI3K/PTEN/Akt signaling and the genesis of cancer
$444,339Nissim Hay · University Of Illinois At Chicago · R01 · FY2024 · CA
A novel strategy to overcome drug resistance in cancer
$444,318Aimee L Edinger · University Of California-Irvine · R01 · FY2024 · CA
Project 2: Deciphering the Dynamic Evolution of the Tumor-Immune Interface
$444,255Stefani Spranger · Massachusetts Institute Of Technology · U54 · FY2025 · CA
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancer
$444,008Alice Berger · Fred Hutchinson Cancer Center · R37 · FY2024 · CA
Reprogramming the Tumor Microenvironment in Ovarian Cancer
$443,654David D Schlaepfer · University Of California, San Diego · R01 · FY2020 · CA
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
$443,556Xinna Zhang · Indiana University Indianapolis · R01 · FY2024 · CA
Spherical Nucleic Acid nano-architectures as first-in-class cGAS agonists for the immunotherapeutic treatment of Glioblastoma.
$443,482Alexander H. Stegh · Washington University · R01 · FY2022 · CA
RCAN 1.4 metastasis suppressor in thyroid cancer
$443,434Matthew D Ringel · Ohio State University · R01 · FY2022 · CA
Project 3: The AMPK Autophagy Pathway as a Metabolic Liability in Pancratic Ductal Adenocarcinoma
$443,412Reuben J Shaw · Salk Institute For Biological Studies · P01 · FY2024 · CA